Search for content, post, videos

Medivir carries out a directed share issue

The board of directors of Medivir has resolved on a directed issue through which the company receives approximately SEK 20 million before issue costs.

The right to subscribe for shares in the Directed Issue shall, with deviation from the shareholders pre-emption rights, belong to Hallberg Management AB (HMAB). HMAB is controlled by Anders Hallberg, former fund manager at HealthInvest Partners AB. The subscription price in the Directed Issue is SEK 2.65 per share and has been determined after negotiations with HMAB.

The reason for the deviation from the shareholders’ pre-emption rights is that the board of directors, in an overall assessment and after careful consideration, considers that a directed issue to HMAB is a time and cost-effective way to provide the company with additional capital to progress the development of the company’s drug candidate fostrox and to give the company an increased financial flexibility as well as that the company, through the Directed Issue, will get a new strategically important, financially strong and long-term shareholder with many years of experience in the industry, which the board of directors’ considers to be positive for the company and its shareholders.

HMAB and Anders Hallberg

HMAB is a limited liability company, which is wholly-owned by Anders Hallberg. Anders Hallberg is one of the founders of the fund company Healthinvest Partners AB. Until January 2024, Anders Hallberg was fund manager in Healthinvest Alpha Fund.

Before the formation of Healthinvest Partners AB, Hallberg worked as both an analyst and a fund manager within the health sector on Carnegie Investment Bank AB.

Hallberg has expressed an interest in being elected to the company’s board of directors, subject to a nomination from the company’s nomination committee and a resolution by the company’s annual general meeting during 2024, it states.

Photo: Medivir